Tandem Diabetes Care (Nasdaq:TNDM) shares got a boost after the market closed today on first-quarter results that beat the consensus forecast.
Shares of TNDM ticked up 6.2% to $17.89 apiece in post-market trading today.
The San Diego-based automated insulin delivery technology company reported losses of $130.56 million. That equals 1.97 per share on sales of $234.4 million for the three months ended March 31, 2025.
Tandem’s bottom line dropped more than threefold despite a year-over-year sales increase of 22.3%. Sales came in well ahead of Wall Street estimates as experts forecast $220.22 million in revenue.
The company continues to increase its insulin pump shipments year-over-year. U.S. shipments grew to more than 17,000 pumps and OUS shipments grew to more than 11,000 pumps.
Additionally, the company said pharmacy benefits now cover approximately 30% of U.S. lives for its Tandem Mobi. Another milestone in the quarter was the release of data supporting the company’s Control-IQ insulin delivery algorithm.
“The strength of our first quarter performance was driven by more than 20% worldwide sales growth, including our highest quarter ever outside the United States,” said John Sheridan, president and CEO. “We are creating new possibilities for people living with diabetes, while delivering record results that align with our 2025 and long-term financial goals for sustained, double-digit sales growth and profitability.”
For the full year, Tandem expects sales between $997 million and $1.007 billion. It said it expects about a $15 million to $20 million headwind outside the U.S. as it prepares for direct commercial operations in select countries.
